Science Advances
Age linked to changing advantages for melanoma mutations
An observational analysis of 5,472 melanomas linked patient age to shifts in which cancer-driving mutations had the greatest advantage.An observational analysis of 5,472 melanomas linked patient age to shifts in which cancer-driving mutations had the greatest advantage.

Cross-sectional · 5,472 peopleMechanisms
Who was studied5,472 melanoma tumors
What changedThe advantage of BRAF V600E mutations in melanoma declined with patient age
The catchCohort-level neutral mutation rates can miss individual exposure histories and bias age trends